Immunotherapy in Breast Cancer

被引:11
|
作者
Dvir, Kathrin [1 ,2 ]
Giordano, Sara [1 ,2 ]
Leone, Jose Pablo [1 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02215 USA
[2] St Elizabeths Med Ctr, Boston, MA 02111 USA
关键词
breast cancer; immunotherapy; checkpoint inhibitors; biomarkers; PEMBROLIZUMAB PLUS CHEMOTHERAPY; DOUBLE-BLIND; INFILTRATING LYMPHOCYTES; TUMOR MICROENVIRONMENT; PHASE-III; SURVIVAL; PLACEBO; TRIAL; ATEZOLIZUMAB; BURDEN;
D O I
10.3390/ijms25147517
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer is a disease encompassing a spectrum of molecular subtypes and clinical presentations, each with distinct prognostic implications and treatment responses. Breast cancer has traditionally been considered an immunologically "cold" tumor, unresponsive to immunotherapy. However, clinical trials in recent years have found immunotherapy to be an efficacious therapeutic option for select patients. Breast cancer is categorized into different subtypes ranging from the most common positive hormone receptor (HR+), human epidermal growth factor receptor 2 (HER2)-negative type, to less frequent HER2- positive breast cancer and triple-negative breast cancer (TNBC), highlighting the necessity for tailored treatment strategies aimed at maximizing patient outcomes. Despite notable progress in early detection and new therapeutic modalities, breast cancer remains the second leading cause of cancer death in the USA. Moreover, in recent decades, breast cancer incidence rates have been increasing, especially in women younger than the age of 50. This has prompted the exploration of new therapeutic approaches to address this trend, offering new therapeutic prospects for breast cancer patients. Immunotherapy is a class of therapeutic agents that has revolutionized the treatment landscape of many cancers, namely melanoma, lung cancer, and gastroesophageal cancers, amongst others. Though belatedly, immunotherapy has entered the treatment armamentarium of breast cancer, with the approval of pembrolizumab in combination with chemotherapy in triple-negative breast cancer (TNBC) in the neoadjuvant and advanced settings, thereby paving the path for further research and integration of immune checkpoint inhibitors in other subtypes of breast cancer. Trials exploring various combination therapies to harness the power of immunotherapy in symbiosis with various chemotherapeutic agents are ongoing in hopes of improving response rates and prolonging survival for breast cancer patients. Biomarkers and precise patient selection for the utilization of immunotherapy remain cardinal and are currently under investigation, with some biomarkers showing promise, such as Program Death Lignat-1 (PDL-1) Combined Positive Score, Tumor Mutation Burden (TMB), and Tumor Infiltrating Lymphocytes (TILs). This review will present the current landscape of immunotherapy, particularly checkpoint inhibitors, in different types of breast cancer.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
    Cejuela, Monica
    Vethencourt, Andrea
    Pernas, Sonia
    CURRENT ONCOLOGY REPORTS, 2022, 24 (12) : 1801 - 1819
  • [2] Liquid biopsy for guiding breast cancer immunotherapy
    Fina, Emanuela
    Vitale, Elsa
    De Summa, Simona
    Gadaleta-Caldarola, Gennaro
    Tommasi, Stefania
    Massafra, Raffaella
    Brunetti, Oronzo
    Rizzo, Alessandro
    IMMUNOTHERAPY, 2025, : 369 - 383
  • [3] Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy
    Chen, Fei
    Chen, Naifei
    Gao, Yangyang
    Jia, Lin
    Lyu, Zheng
    Cui, Jiuwei
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [4] Tumor microenvironment and immunotherapy for triple-negative breast cancer
    Guo, Zijie
    Zhu, Ziyu
    Lin, Xixi
    Wang, Shenkangle
    Wen, Yihong
    Wang, Linbo
    Zhi, Lili
    Zhou, Jichun
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [5] Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches
    Geurts, Veerle
    Kok, Marleen
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (06) : 628 - 643
  • [6] Advances on immunotherapy in breast cancer
    Athreya, Kanthi
    Ali, Sonia
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 (01) : 30 - 37
  • [7] Immunotherapy and breast cancer: an overview
    Mezni, Essia
    Behi, Khalil
    Goncalves, Anthony
    CURRENT OPINION IN ONCOLOGY, 2022, 34 (05) : 587 - 594
  • [8] PET/CT in Patients with Breast Cancer Treated with Immunotherapy
    Vaz, Sofia C.
    Graff, Stephanie L.
    Ferreira, Arlindo R.
    Debiasi, Marcio
    de Geus-Oei, Lioe-Fee
    CANCERS, 2023, 15 (09)
  • [9] Current Treatment and Future Trends of Immunotherapy in Breast Cancer
    Elliott, Mitchell J.
    Wilson, Brooke
    Cescon, David W.
    CURRENT CANCER DRUG TARGETS, 2022, 22 (08) : 667 - 677
  • [10] Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy
    Magbanua, Mark Jesus M.
    Gumusay, Ozge
    Kurzrock, Razelle
    van't Veer, Laura J.
    Rugo, Hope S.
    FRONTIERS IN ONCOLOGY, 2022, 12